At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Mar 25, 2026 at 07:00 ET
C4 Therapeutics has dosed the first patient in a Phase 1b trial combining its investigational drug cemsidomide with Pfizer's FDA-approved elranatamab for relapsed/refractory multiple myeloma. The trial aims to evaluate safety and preliminary efficacy, with data expected in mid-2027, representing a strategic step in advancing cemsidomide across multiple treatment lines.
- First patient dosed in a Phase 1b trial combining cemsidomide with elranatamab (ELREXFIO®) for relapsed/refractory multiple myeloma (RRMM).
- Trial will evaluate cemsidomide at 50 µg, 75 µg, and 100 µg doses in combination with elranatamab; up to 54 patients to be enrolled.
- Primary endpoint is safety and tolerability; secondary endpoints include overall response rate, MRD-negative complete response, and duration of response.
- Pfizer is providing elranatamab at no cost under a clinical trial collaboration agreement; C4T is sponsoring and conducting the trial.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access